Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Datametrex Acquires Arbutus Health And Wellness Inc.

TORONTO, ON / ACCESS Newswire / June 6, 2025 / Datametrex AI Limited (the "Company" or "Datametrex'') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that further to its news release dated April 1, 2025, it has completed the acquisition of all of the issued and outstanding share capital of Arbutus Health and Wellness Inc. ("Arbutus Health"), a multidisciplinary medical clinic in Vancouver, Canada.

Arbutus Health provides walk-in services, family medicine, skin laser treatments, and other specialty healthcare services in a single location. Once operational, the clinic will be staffed by licensed healthcare professionals and will provide patients with access to multiple medical services without requiring multiple referrals.

The acquisition of Arbutus was completed by way of a share exchange agreement dated June 5, 2025 between the Company, Arbutus and the shareholders of Arbutus pursuant to which Datametrex acquires 100% of the issued and outstanding shares of Arbutus Health, an arm's length party, in exchange for an aggregate of 11,000,000 common shares of Datametrex at a deemed value of $0.10 per share (the "Payment Shares"). As a result of the transaction, Arbutus is now a wholly-owned subsidiary of Datametrex.

Upon completion of the Transaction, Paul Haber, the CEO of the Company, commented, "We are excited to finalize this agreement and are eager to integrate the Arbutus Health team into Datametrex. This acquisition marks a key milestone in broadening our product portfolio and enhancing our presence in the healthcare sector."

Issuance of the Payment Shares is subject to the receipt of regulatory approvals including, without limitation, the final approval of the TSX Venture Exchange ("TSXV") and other conditions.

Datametrex has not assumed any debt of Arbutus and the proposed acquisition will not constitute a fundamental change or result in a change of business for the Company, nor is it expected to result in a change of control of the Company within the meaning of applicable securities laws and defined in the polices of the TSXV.

About Arbutus Health

Arbutus Health is a multidisciplinary medical clinic designed to address wait times and fragmented care in Canada's health system. Walk-in services, family doctors, skin laser treatments, and other specialties are integrated under one roof to provide timely and comprehensive care without requiring multiple referrals. Staffed by licensed healthcare professionals, patient satisfaction will be enhanced through innovative, efficient, and high-quality healthcare solutions.

About Datametrex

Datametrex is an innovative leader in Technology Solutions, Artificial Intelligence, Healthcare, and Mobile Gaming. The Company excels in delivering tools and solutions that enhance operational efficiencies and business outcomes. With a commitment to innovation, Datametrex is dedicated to supporting enterprises by setting a new standard for business protocols through cutting-edge technology.

For more on Datametrex, please visit our Company website.

For Additional Information

Paul Haber, C.P.A., C.A., C.Dir
CEO & Chairman
info@datametrex.com
(416) 318-6501

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains "forward-looking statements," which involve risks, uncertainties, and factors that could cause actual results to differ materially from those anticipated. These statements are not historical facts and are generally identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," and similar expressions. Such statements include expectations related to healthcare business and other Company plans.

While Datametrex believes the forward-looking information is reasonable as of the date of this release, these statements involve assumptions, risks, and uncertainties that could cause actual outcomes to differ. Key factors include general economic conditions, legislative and regulatory developments, access to capital, industry competition, and the Company's ability to execute its strategies. The Company does not undertake to update these statements, except as required by law. Readers are advised not to place undue reliance on forward-looking information.

Factors that could cause actual results to differ materially are detailed under "Risk Factors" in Datametrex's management's discussion and analysis and available on the Company's profile at www.sedarplus.ca.

This release does not constitute an offer to sell or a solicitation to buy, nor shall it constitute an offer, solicitation, or sale in any jurisdiction where such would be unlawful prior to registration or qualification under applicable securities laws. We seek Safe Harbor.

SOURCE: Datametrex AI Ltd.



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.